Browsing Tag
Namodenoson
2 posts
Can Namodenoson overcome immunotherapy resistance in advanced pancreatic adenocarcinoma?
Can-Fite BioPharma Ltd. advances Namodenoson into Phase 2b pancreatic cancer testing. Discover what this means for immunotherapy economics.
Can an A3 adenosine receptor agonist change the treatment ceiling in advanced pancreatic cancer
Can Can-Fite BioPharma Ltd.’s namodenoson change pancreatic cancer outcomes? Explore what its Phase 2a data means for investors and oncology strategy.